Fibroblast was acquired by Cerner Corporation in October 2020. Fibroblast automates the referral process by empowering providers with an easy to use, end-to-end referral tool. By closing the referral loop, Fibroblasts prevents patient leakage, increasing revenues for fee-for-service organizations and lowering risks for accountable care organizations. Fibroblast delivers a clear, compelling return on investment.